8,600 Shares in IQVIA Holdings Inc. $IQV Acquired by Louisiana State Employees Retirement System

Louisiana State Employees Retirement System acquired a new stake in IQVIA Holdings Inc. (NYSE:IQV) in the first quarter, Holdings Channel reports. The institutional investor acquired 8,600 shares of the medical research company’s stock, valued at approximately $1,467,000.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Ameliora Wealth Management Ltd. bought a new position in shares of IQVIA in the fourth quarter worth approximately $25,000. International Assets Investment Management LLC purchased a new position in shares of IQVIA during the fourth quarter valued at about $27,000. Gilpin Wealth Management LLC bought a new position in shares of IQVIA in the 4th quarter worth approximately $27,000. CrossGen Wealth LLC purchased a new position in IQVIA during the fourth quarter valued at $28,000. Finally, Activest Wealth Management lifted its position in IQVIA by 590.0% during the 4th quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 118 shares during the period. 89.62% of the stock is currently owned by institutional investors.

IQVIA Price Performance

Shares of NYSE:IQV opened at $206.38 on Friday. The firm has a market cap of $34.44 billion, a price-to-earnings ratio of 25.57, a P/E/G ratio of 1.74 and a beta of 1.20. The firm has a fifty day moving average price of $176.33 and a 200 day moving average price of $189.18. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75. IQVIA Holdings Inc. has a fifty-two week low of $154.50 and a fifty-two week high of $247.04.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The firm had revenue of $4.15 billion for the quarter, compared to analysts’ expectations of $4.10 billion. During the same period in the previous year, the firm posted $2.70 earnings per share. The business’s revenue was up 8.4% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, sell-side analysts expect that IQVIA Holdings Inc. will post 11.6 earnings per share for the current fiscal year.

IQVIA announced that its board has initiated a stock repurchase plan on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s board of directors believes its shares are undervalued.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on IQV shares. HSBC set a $210.00 target price on IQVIA in a report on Wednesday, June 3rd. Morgan Stanley reaffirmed an “equal weight” rating and issued a $200.00 target price (down from $225.00) on shares of IQVIA in a research report on Wednesday, June 17th. Weiss Ratings cut shares of IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Wall Street Zen downgraded IQVIA from a “buy” rating to a “hold” rating in a research report on Saturday, June 27th. Finally, Robert W. Baird lifted their price target on shares of IQVIA from $230.00 to $249.00 and gave the company an “outperform” rating in a report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, IQVIA currently has a consensus rating of “Moderate Buy” and an average target price of $222.00.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.